Innovative vaccine candidate effective against disease in preclinical models
Researchers from Inserm and the University of Paris-Est Créteil at the Vaccine Research Institute (VRI), the CEA and the University of Paris-Saclay have developed a vaccine targeting key cells of the immune system, the dendritic cells.
It has been shown to be effective in preclinical models, inducing a protective immune response against the virus. Initially, the researchers believe that this vaccine could be useful for convalescent or previously vaccinated individuals whose immune response has begun to decline, in order to “boost” their immunity.
Human clinical trials are scheduled to begin in 2022. The results were published on September 1, 2021 in the journal Nature Communications
Regulation of the inflammasome by NLRP3 post-translational modification :
«Bénédicte PY - 13h - Webconférence Zoom»
When economics meets health – 1st SID FSEG-IMRB seminar :
«Thomas BARNAY (Laboratoire ERUDITE, Université Paris-Est-Créteil, chercheur invité à l'Université de Harvard) et Florence CANOUÏ-POITRINE (IMRB-U955, équipe Bastuji-Garin) - 15h - Visioconférence Zoom»
When environmental sciences meet health sciences – 6th OSU-IMRB seminar (videoconference) : “Les microfaunes : du sol au poumon” :
«Philippe MORA (IESS) and Françoise BOTTEREL (Dynamic Biology, UPEC) - From 12pm to 2pm - By Videoconference - Registration required»
All incoming seminars